<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144713</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-10</org_study_id>
    <nct_id>NCT03144713</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis</brief_title>
  <official_title>Randomized Trial Comparing the Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Study Population: Patients admitted or seen in Out Patient Department, Department of
           Hepatology, Institute of Liver and Biliary Sciences.

        -  Study Design: Prospective Open Labeled Randomized Controlled Trial.

        -  Study Period: January 2017 to December 2017

        -  Intervention- Subjects will be randomized to 3 groups

        -  All patients will receive Standard medical therapy - Albumin-8g/L of tap- one half of
           dose at beginning of tap and rest half after 6 hours of tapping.

      Group A - Subjects will receive Terlipressin 1mg intravenous bolus at the onset of
      paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose.
      ( total -3mg) Group B - Midodrine 7.5 mg TDS x 3 days Group C - Standard medical therapy only

        -  Monitoring and Assessment: Clinical evaluation will be done at regular intervals.

        -  Adverse Effects: Rise in blood pressure, arrthymias, hyponatremia and rarely
           cardiovascular side effects have been noted.

        -  Stopping Rule: Development of PICD, hypertension ( BP&gt;160/90mmhg-JNC class II)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Paracentesis Induced Circulatory Dysfunction (PICD).</measure>
    <time_frame>Day 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admission withing 28 days in all the 3 groups</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Hyponatremia in all the 3 groups</measure>
    <time_frame>Day 28</time_frame>
    <description>Hyponatremia is defined as S.Na &lt; 130 meq/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Hepatic Encephalopathy in all the 3 groups</measure>
    <time_frame>Day 28</time_frame>
    <description>Hepatic Encephalopathy defined as West Haven Grade &gt; 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of ascites in all the 3 groups</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Acute Kidney Injury in all the 3 groups</measure>
    <time_frame>Day 28</time_frame>
    <description>Acute Kidney Injury is defined as increase S.Creatinine by more than 0.3 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival in all the 3 groups</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Terlipressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midodrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midodrine 7.5 mg thrice daily for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)</description>
    <arm_group_label>Terlipressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)</description>
    <arm_group_label>Midodrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.</description>
    <arm_group_label>Standard Medical Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with cirrhosis who undergo Large volume paracentesis (&gt; 5L)

          2. Patients with age from 18-75 years

        Exclusion Criteria:

          1. Renal failure ( Creatinine&gt;1.5mg/dl)

          2. Recent Gastrointestinal bleeding within 7 days

          3. Spontaneous bacterial Peritonitis

          4. Patients with Cardiovascular disease (Electrocardiogram, 2D Echo)

          5. Systemic arterial hypertension ( &gt;160/90mmhg) Presence of hepatocellular carcinoma or
             portal vein thrombosis, Budd chiari syndrome

          6. Patients with active untreated sepsis

          7. Pregnancy

          8. Patients with hepatic encephalopathy

          9. No use of drugs affecting systemic hemodynamic 3 days prior to enrollment

         10. Refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Anand Kulkarni, MD</last_name>
    <phone>01146300000</phone>
    <email>anandvk90@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>July 1, 2017</last_update_submitted>
  <last_update_submitted_qc>July 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

